SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-021506
Filing Date
2023-05-12
Accepted
2023-05-12 08:03:53
Documents
13
Period of Report
2023-05-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K impl-20230512.htm   iXBRL 8-K 70753
2 EX-99.1 impl-ex99_1.htm EX-99.1 259602
  Complete submission text file 0000950170-23-021506.txt   478917

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT impl-20230512.xsd EX-101.SCH 2459
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT impl-20230512_pre.xml EX-101.PRE 12029
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT impl-20230512_lab.xml EX-101.LAB 19074
7 EXTRACTED XBRL INSTANCE DOCUMENT impl-20230512_htm.xml XML 5109
Mailing Address 201 ELLIOTT AVE. W SUITE 260 SEATTLE WA 98119
Business Address 201 ELLIOTT AVE. W SUITE 260 SEATTLE WA 98119 206-568-1466
IMPEL PHARMACEUTICALS INC (Filer) CIK: 0001445499 (see all company filings)

IRS No.: 263058238 | State of Incorp.: DE | Fiscal Year End: 0426
Type: 8-K | Act: 34 | File No.: 001-40353 | Film No.: 23913229
SIC: 2834 Pharmaceutical Preparations